Pfizer Says It Has Over 50% Enrollment for Coronavirus Vaccine Candidate Trial
One of the leading COVID-19 vaccine candidates currently in development is getting closer to a potential finish line. Pfizer (NYSE: PFE) said on Wednesday that the recruitment for the crucial U.S. phase 3 clinical trial of its BNT162b2 is more than 50% complete. The company is aiming to recruit 30,000 individuals for the trial.
The news was reported by Pfizer vaccine research and development scientist Dr. Nicholas Kitchin at a meeting of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.
Image source: Getty Images.
Source Fool.com
